168 related articles for article (PubMed ID: 24081388)
21. US Food and Drug Administration approval of drugs for the treatment of prostate cancer: a new era has begun.
D'Amico AV
J Clin Oncol; 2014 Feb; 32(4):362-4. PubMed ID: 24344221
[No Abstract] [Full Text] [Related]
22. [Radium dichloride-223 improves symptoms including in the daily clinic].
Kirchner V; Papazyan JP
Rev Med Suisse; 2015 Nov; 11(493):2083. PubMed ID: 26685654
[No Abstract] [Full Text] [Related]
23. Radium-223: the newest option in metastatic castration-resistant prostate cancer.
Sartor O
Clin Adv Hematol Oncol; 2013 Dec; 11(12):801-3. PubMed ID: 24893286
[No Abstract] [Full Text] [Related]
24. Counterpoints: Which should be used first in symptomatic metastatic castration-resistant prostate cancer, docetaxel or radium? Radium-223 is the preferred therapy in bone-predominant symptomatic metastatic castration-resistant prostate cancer.
Li J; Armstrong AJ
Clin Adv Hematol Oncol; 2015 May; 13(5):293-8. PubMed ID: 26352773
[No Abstract] [Full Text] [Related]
25. Updated:
Boni G; Monari F
Tumori; 2019 Jun; 105(3):271. PubMed ID: 30866748
[No Abstract] [Full Text] [Related]
26. Alpha-emitter radium-223 in the management of solid tumors: current status and future directions.
Nilsson S
Am Soc Clin Oncol Educ Book; 2014; ():e132-9. PubMed ID: 24857093
[TBL] [Abstract][Full Text] [Related]
27. Single-center experience with radium-223 in patients with castration-resistant prostate cancer and bone metastases.
Kapoor A; Wong NC; Wang Y; Mukherjee S; Hotte S; Dayes I; Lukka H
Asian J Androl; 2020; 22(4):437-438. PubMed ID: 31535625
[No Abstract] [Full Text] [Related]
28. CApecitabine plus Radium-223 (Xofigo™) in breast cancer patients with BONe metastases (CARBON): study protocol for a phase IB/IIA randomised controlled trial.
Coleman R; Brown J; Rathbone E; Flanagan L; Reid A; Kendall J; Howell S; Twelves C; Palmieri C; Anand A; MacPherson I; Brown S
Trials; 2020 Jan; 21(1):89. PubMed ID: 31941523
[TBL] [Abstract][Full Text] [Related]
29. One-Year Postapproval Clinical Experience with Radium-223 Dichloride in Patients with Metastatic Castrate-Resistant Prostate Cancer.
Jadvar H; Challa S; Quinn DI; Conti PS
Cancer Biother Radiopharm; 2015 Jun; 30(5):195-9. PubMed ID: 25746633
[TBL] [Abstract][Full Text] [Related]
30. Highlights in Metastatic Prostate Cancer From the 2016 American Society of Clinical Oncology Genitourinary Cancers Symposium: Commentary.
Shore ND
Clin Adv Hematol Oncol; 2016 Apr; 14(4 Suppl 5):17-9. PubMed ID: 27167847
[No Abstract] [Full Text] [Related]
31. Analysis of Unusual Adverse Effects After Radium-223 Dichloride Administration.
Frantellizzi V; Pontico M; Pani A; Pani R; De Vincentis G
Curr Radiopharm; 2020; 13(2):159-163. PubMed ID: 31560295
[TBL] [Abstract][Full Text] [Related]
32. Radium 223 dichloride: a multidisciplinary approach to metastatic castration-resistant prostate cancer.
Borsò E; Boni G; Galli L; Ricci S; Farnesi A; Mazzarri S; Cianci C; Mariani G; Falcone A
Future Oncol; 2015; 11(2):323-31. PubMed ID: 25075962
[TBL] [Abstract][Full Text] [Related]
33. Advanced prostate cancer gets a new foe.
Johns Hopkins Med Lett Health After 50; 2013 Aug; 25(7):8. PubMed ID: 24396891
[No Abstract] [Full Text] [Related]
34. Radium-223 dichloride for the treatment of bone metastatic castration-resistant prostate cancer: an evaluation of its safety.
Nilsson S
Expert Opin Drug Saf; 2015 Jul; 14(7):1127-36. PubMed ID: 26022669
[TBL] [Abstract][Full Text] [Related]
35. Updates on radium-223 for castration-resistant prostate cancer presented at the Genitourinary Cancers Symposium, January 7-9, 2016, San Francisco, California.
Barkin J
Can J Urol; 2016 Jun; 23(3):8306-7. PubMed ID: 27347626
[No Abstract] [Full Text] [Related]
36. Management of metastatic castration-resistant prostate cancer: A focus on radium-223: Opinions and suggestions from an expert multidisciplinary panel.
Baldari S; Boni G; Bortolus R; Caffo O; Conti G; De Vincentis G; Monari F; Procopio G; Santini D; Seregni E; Valdagni R
Crit Rev Oncol Hematol; 2017 May; 113():43-51. PubMed ID: 28427521
[TBL] [Abstract][Full Text] [Related]
37. New radiation therapy prolongs metastatic prostate cancer survival.
McBride D
ONS Connect; 2013 Sep; 28(3):49. PubMed ID: 24028051
[No Abstract] [Full Text] [Related]
38. Hungry bone syndrome secondary to prostate cancer successfully treated with radium therapy.
Garla VV; Salim S; Kovvuru KR; Subauste A
BMJ Case Rep; 2018 Jul; 2018():. PubMed ID: 29982185
[TBL] [Abstract][Full Text] [Related]
39. Radium-223 dichloride: a new paradigm in the treatment of prostate cancer.
Anido Herranz U; Fernández Calvo O; Afonso Afonso FJ; Rodríguez Martínez de Llano S; Lázaro Quintela M; León Mateos L; Vázquez Estévez S; Antón Aparicio LM
Expert Rev Anticancer Ther; 2015 Mar; 15(3):339-48. PubMed ID: 25555355
[TBL] [Abstract][Full Text] [Related]
40. Therapeutic effect of RA223 in the management of breast cancer bone metastases.
Costa RP; Tripoli V; Princiotta A; Murabito A; Licari M; Piazza D; Verderame F; Pinto A
Clin Ter; 2019; 170(1):e1-e3. PubMed ID: 30789190
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
